Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) was the target of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 6,134 shares, a decrease of 62.4% from the July 30th total of 16,311 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,460 shares, the days-to-cover ratio is currently 1.1 days.

Elekta Price Performance

OTCMKTS:EKTAY traded up $0.13 during trading hours on Friday, reaching $5.63. 686 shares of the company’s stock were exchanged, compared to its average volume of 3,758. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $2.08 billion, a P/E ratio of -46.91 and a beta of 1.01. Elekta has a 12 month low of $4.35 and a 12 month high of $6.93. The business’s 50-day simple moving average is $5.20 and its two-hundred day simple moving average is $5.70.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The company had revenue of $372.30 million during the quarter. Elekta had a positive return on equity of 13.31% and a negative net margin of 2.38%. Sell-side analysts expect that Elekta will post 0.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Elekta currently has an average rating of “Reduce”.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.